x Preliminary
Proxy
Statement
|
o
Confidential,
for Use of the
Commission Only (as permitted by Rule 14a-6(e)(2))
|
o
Definitive
Proxy
Statement
|
o
Definitive
Additional
Materials
|
o
Soliciting
Material Under Rule
14a-12
|
|
|
o
|
No
fee required.
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant
to
Exchange Act Rule 0-11:
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
(5)
|
Total
fee paid:
|
|
ý
|
Fee
paid previously with preliminary materials.
|
|
|
|
|
o
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid
previously. Identify the previous filing by registration statement
number,
or the form or schedule and the date of its filing.
|
|
(1)
|
Amount
previously paid: N/A
|
|
(2)
|
Form,
Schedule or Registration Statement No.: N/A
|
|
(3)
|
Filing
Party: N/A
|
|
(4)
|
Date
Filed: N/A
|
|
|
|
Sincerely,
|
|
|
|
/s/
Dan Grey
|
|
|
|
Dan
Grey
|
|
President
and Chief Executive Officer
|
|
|
|
By
Order of the Board of Directors,
|
|
|
|
/s/
David W. Brunton
|
|
|
|
David
W. Brunton
|
|
Secretary
|
|
1
|
WHERE
YOU CAN FIND MORE INFORMATION
|
1
|
SUMMARY
TERM SHEET FOR THE MERGER AND PRIVATE PLACEMENT
|
5
|
RISK
FACTORS
|
13
|
Risk
Relating to the Transactions
|
13
|
Risk
Relating to SBE after the Transactions
|
14
|
Risks
Related to PyX’s Business
|
15
|
THE
COMPANIES
|
17
|
SBE
|
17
|
PyX
|
17
|
THE
MERGER AND THE PRIVATE PLACEMENT
|
18
|
Background
of the Merger and the Private Placement
|
18
|
Reasons
for the Merger and the Private Placement
|
20
|
Opinion
of Our Financial Advisor
|
22
|
Regulatory
Approvals Relating to the Transactions
|
29
|
Dissenters’
Rights Relating to the Transactions
|
29
|
Interests
of Certain Persons in the Transactions
|
29
|
PROPOSAL
1 - APPROVAL OF THE MERGER, THE MERGER AGREEMENT AND THE ISSUANCE
OF
SHARES OF OUR COMMON STOCK AND ASSUMPTION OF OPTIONS TO PURCHASE
SHARES OF
OUR COMMON STOCK IN THE MERGER
|
30
|
General
|
30
|
Effective
Time of the Merger
|
30
|
Treatment
of Stock Options
|
30
|
Surrender
and Exchange of Share Certificates
|
31
|
Escrow
|
31
|
Representations
and Warranties
|
31
|
Certain
Covenants
|
33
|
Indemnification
|
36
|
Conditions
Precedent
|
36
|
Termination
|
37
|
Waivers
|
37
|
Amendments
|
38
|
Fees
and Expenses
|
38
|
Accounting
Treatment of the Merger
|
38
|
Shareholder
Agreement
|
38
|
Voting
Agreement
|
39
|
Past
Contacts, Transactions or Negotiations
|
39
|
Recommendation
of our Board of Directors
|
39
|
COMPARATIVE
PER SHARE MARKET PRICE AND DIVIDEND INFORMATION
|
40
|
Unaudited
Pro forma Consolidated Financial Statements of SBE
|
42
|
SELECTED
FINANCIAL DATA OF PYX
|
46
|
DESCRIPTION
OF PYX’S BUSINESS
|
47
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
|
|
RESULTS
OF OPERATIONS OF PYX
|
50
|
PROPOSAL
2 - APPROVAL OF THE UNIT SUBSCRIPTION AGREEMENT AND THE ISSUANCE
OF SHARES
OF SERIES A PREFERRED STOCK IN THE PRIVATE PLACEMENT
|
62
|
General
|
62
|
Per
Unit Purchase Price
|
63
|
Closing
of the Private Placement
|
63
|
Representations
and Warranties
|
63
|
Certain
Covenants
|
65
|
Indemnification
|
65
|
Conditions
Precedent
|
65
|
Warrants
|
65
|
Investor
Rights Agreement
|
66
|
Registration
Rights
|
66
|
The
Voting Agreement
|
66
|
OTHER
MATTERS
|
67
|
•
|
the
extent of our ability to integrate the operations of PyX with our
own
operations;
|
•
|
our
ability to develop and market the Internet Small computer System
Interface, or iSCSI, software;
|
•
|
the
effect of any unknown liabilities of PyX that materialize after the
transactions;
|
•
|
the
effect of the transactions on our market price;
|
•
|
the
factors discussed under “Risk Factors,” beginning on page [___];
and
|
•
|
other
risks referenced from time to time in our filings with the Securities
and
Exchange Commission, or SEC, including our annual report on Form 10-K
for our fiscal year ended October 31, 2004 and our quarterly
report
on Form 10-Q for the quarter ended April 30, 2005, copies of which
accompany this proxy statement.
|
|
|
|
Proposal
1 —
To approve a merger agreement between PyX, PyX Acquisition Sub, LLC,
our
newly-formed, wholly owned subsidiary (referred to in the proxy statement
as “Merger Sub”) and us and the transactions contemplated by the merger
agreement, including the merger of PyX with and into Merger Sub,
the
issuance of 2,561,050 shares of our common stock to the PyX shareholders,
and the assumption of options to purchase up to an additional 2,038,950
shares of our common stock; and
|
|
|
|
Proposal
2 —
To approve the issuance of units consisting of one share of our common
stock and a warrant to purchase an additional one-half share of our
common
stock, for aggregate gross proceeds to us of $5,150,000, in a private
placement pursuant to the terms of a unit subscription agreement
between
AIGH Investment Partners, LLC and certain other unaffiliated purchasers
and us.
|
•
|
To
vote in person, come to the special meeting and we will give you
a ballot
when you arrive.
|
•
|
To
vote using the proxy card, simply complete, sign and date the enclosed
proxy card and return it promptly in the envelope provided. If you
return
your signed proxy card to us before the special meeting, we will
vote your
shares as you direct.
|
•
|
You
may submit another properly completed proxy card with a later
date;
|
•
|
You
may send a written notice that you are revoking your proxy to our
Secretary at 2305 Camino Ramon, Suite 200, San Ramon, California
94583;
or
|
•
|
You
may attend the special meeting and vote in person. However, simply
attending the special meeting will not, by itself, revoke your
proxy.
|
•
|
the
issued and outstanding shares of PyX common stock will be converted
into
the right to receive an aggregate of 2,561,050 shares of our common
stock,
or approximately 49% of the outstanding shares of our common stock
based
on the number of shares outstanding on April 29, 2005 and 24.6% of
the
outstanding shares of our common stock after the closing of the private
placement, assuming no further issuances of shares of our common
stock and
no exercise of outstanding stock options or warrants;
and
|
•
|
the
issued and outstanding options to purchase shares of PyX common stock
will
be assumed by us and converted into the right to receive an aggregate
of
2,038,950 shares of our common stock upon exercise of the underlying
options, or approximately 38.8% of the outstanding shares of our
common
stock based on the number of shares outstanding on April 29, 2005
and
19.6% of the outstanding shares of our common stock after the closing
of
the private placement, assuming no further issuances of shares of
our
common stock and no exercise of outstanding stock options or warrants.
The
exercise price of the assumed options will be $2.17 per share of
our
common stock issuable upon exercise of the underlying option. The
options
will be subject to the same terms and conditions as were in place
prior to
the merger.
|
•
|
solicit
or encourage the initiation of any inquiry, proposal or offer relating
to
an alternative business combination proposal;
|
•
|
participate
in any discussions or negotiations or enter into any agreement with,
or
furnish any non-public information to, any person relating to or
in
connection with any alternative business combination proposal;
or
|
•
|
consider,
entertain or accept any proposal or offer from any person relating
to any
alternative business combination
proposal.
|
•
|
accuracy
of the other party’s representations and warranties and compliance by the
other party with their covenants;
|
•
|
approval
by our stockholders of the issuance of shares of our common stock
in
connection with the merger;
|
•
|
execution
and delivery of certain ancillary documents attached to the merger
agreement as exhibits;
|
•
|
receipt
of an officer’s certificate certifying the accuracy of each party’s
representations and warranties and satisfaction of certain conditions;
|
•
|
our
entering into a definitive agreement with respect to the private
placement;
|
•
|
absence
of legal prohibitions to the completion of the
merger;
|
•
|
absence
of legal proceedings challenging the merger, seeking recovery of
a
material amount in damages or seeking to prohibit or limit the exercise
of
any material right with respect to our ownership of stock in Merger
Sub or
the PyX shareholders’ ownership of our common stock;
and
|
•
|
no
material adverse effect will have occurred and no circumstance exists
that
could reasonably be expected to have or result in a material adverse
effect with respect to us or PyX.
|
•
|
holders
of no more than 5% of the outstanding PyX common stock will have
elected
to exercise their dissenters’ rights in connection with the
merger;
|
•
|
receipt
of required third-party consents;
and
|
•
|
amendment
of PyX’s current customer agreement with Pelco in a manner acceptable to
us.
|
•
|
if
it is reasonably determined by that party that timely satisfaction
of any
of the conditions precedent to the obligations of that party to effect
the
merger and consummate the transactions contemplated by the merger
agreement has become impossible;
|
•
|
if
any of the conditions precedent to the obligations of that party
to effect
the merger and consummate the transactions contemplated by the merger
agreement has not been satisfied as of the agreed closing date;
or
|
•
|
the
merger has not been completed on or before July 31,
2005.
|
•
|
execution
and delivery of the investor rights
agreement;
|
•
|
accuracy
of the representations and warranties of the parties and compliance
by the
parties with their respective
covenants;
|
•
|
approval
by our stockholders of Proposals 1 and
2;
|
•
|
our
listing status on the Nasdaq SmallCap
Market;
|
•
|
completion
of the merger; and
|
•
|
entry
by PyX into a reseller agreement with LSI
Logic.
|
1.
|
whether
the combination of our existing solutions with PyX’s Internet Small
Computer System Interface, or iSCSI, software meets a significant
customer
need;
|
2.
|
whether
the combined company will be in the best position to capture market
share
as iSCSI technology is adopted in the marketplace;
and
|
3. | whether our products with PyX’s products will increase their respective functionality. |
1.
|
the
price to be paid for the common stock by the purchasers in the private
placement;
|
2.
|
limited
sources of capital for companies in SBE’s financial position;
and
|
3.
|
our
immediate need for additional capital to develop PyX’s iSCSI software
solutions in order to enhance SBE’s future
revenues.
|
1.
|
information
relating to the business, assets, management, competitive position
and
operating performance of PyX, including the prospects of SBE if it
were to
continue without acquiring PyX;
|
2.
|
the
financial presentation of Houlihan Lokey, including its opinion described
under “Opinion of Our Financial Advisor” on page [___], to the effect
that, as of the date of the opinion, the merger consideration is
fair to
our stockholders from a financial point of view;
and
|
3.
|
our
need following the transactions for capital to develop the iSCSI
software
solutions, fund the costs associated with merger and provide sufficient
operating capital to support our operations for the near
term.
|
1.
|
all
the reasons described above under “Reasons for the Merger and the Private
Placement”;
|
2.
|
the
judgment, advice and analyses of our senior management, including
their
favorable recommendation of the merger and the private
placement;
|
3.
|
alternatives
to the merger and the private
placement;
|
4.
|
the
presentations by and discussions with our senior management and
representatives of our counsel and Houlihan Lokey regarding the terms
and
conditions of the unit subscription agreement and the private
placement;
|
5.
|
the
presentations by and discussions with our senior management and
representatives of our counsel regarding the terms and conditions
of the
merger agreement and the merger;
|
6.
|
that
while the merger and the private placement are likely to be completed,
there are risks associated with completing the transactions and,
as a
result of conditions to the completion of the transactions, it is
possible
that the transactions may not be completed even if approved by our
stockholders and PyX’s shareholders;
and
|
7.
|
the
risk that the synergies and benefits sought in the merger might not
be
fully achieved or achieved at all.
|
1.
|
reviewed
our Annual Report on Form 10-K for the fiscal year ended October
31, 2004,
and our quarterly report on Form 10-Q for the first quarter ended
January
31, 2005, which our management has identified as being the most current
financial statements available;
|
2.
|
reviewed
PyX’s unaudited financial statements for the fiscal years ended December
31, 2003 and 2004 and interim financial statements for the two-month
period ended February 28, 2005;
|
3.
|
reviewed
copies of the following agreements:
|
•
|
the
Term Sheet between us and PyX, dated February 7,
2005;
|
•
|
the
Agreement and Plan of Merger and Reorganization between us and PyX,
dated
March 28, 2005;
|
•
|
the
Form of Shareholder Agreement between us and the shareholders of
PyX;
|
•
|
the
Form of Noncompetition Agreement;
|
•
|
the
Form of General Release;
|
•
|
the
Form of Affiliate Agreement;
|
•
|
the
Form of Escrow Agreement;
|
•
|
the
Disclosure Schedule of PyX, dated March 28,
2005.
|
4.
|
reviewed
the form of legal opinion of Orrick, Herrington & Sutcliffe LLP, dated
March 28, 2005;
|
5.
|
met
with certain members of the senior management of PyX and us to discuss
the
operations, financial condition, future prospects and projected operations
and performance of PyX and us, and met with representatives of our
legal
counsel to discuss certain matters;
|
6.
|
visited
our facilities and business
offices;
|
7.
|
reviewed
forecasts and projections prepared by our management with respect
to us on
a stand-alone basis and in combination with PyX for the fiscal years
ended
October 31, 2005 and 2006;
|
8.
|
reviewed
the historical market prices and trading volume for our publicly-traded
securities;
|
9.
|
reviewed
certain other publicly-available financial data for certain companies
that
Houlihan Lokey deemed comparable to us and PyX, and publicly-available
prices and premiums paid in other transactions that they considered
similar to the merger; and
|
10.
|
conducted
such other studies, analyses and inquiries as Houlihan Lokey deemed
appropriate.
|
Enterprise
Value Indication from Operations
|
||||
Market
Approach
|
Low
|
High
|
||
(figures
in thousands)
|
||||
Private
Financing Methodology
|
$7,000
|
--
|
$12,000
|
|
Previous
PyX Financing
|
$10,000
|
--
|
$10,000
|
|
Concluded
Enterprise Value
|
|
$7,000
|
--
|
$12,000
|
Concluded
Equity Value
|
|
$7,000
|
--
|
$12,000
|
•
|
enterprise
value, or EV, which is the market value of equity, or MVE, of the
comparable company, plus all interest-bearing debt, less cash and
cash
equivalents, to our latest 12 months, or LTM, of
revenues;
|
•
|
EV
to estimated calendar year 2005
revenues;
|
•
|
EV
to estimated calendar year 2006
revenues;
|
EV
/ Revenues
|
||||||
LTM
|
CY05
|
CY06
|
||||
Selected
Comparables
|
|
|||||
Performance
Technologies, Inc.
|
|
1.75x
|
1.59x
|
1.39x
|
||
Radisys
Corporation
|
|
0.99x
|
0.92x
|
0.79x
|
||
Adaptec,
Inc.
|
|
0.94x
|
0.85x
|
0.76x
|
||
SBS
Technologies, Inc.
|
|
0.93x
|
0.83x
|
0.72x
|
||
Interphase
Corporation
|
|
0.71x
|
NA
|
NA
|
(figures
in thousands, except per share values)
|
|||||||
Enterprise
Value Indication from Operations
|
|||||||
Fundamental
Valuation of SBE
|
Low
|
High
|
|||||
Market
Multiple Methodology
|
$
|
11,100
|
$
|
15,600
|
|||
Enterprise
Value from Operations using Market Approach
|
$
|
11,100
|
$
|
15,600
|
|||
Add:
Excess Cash (1)
|
--
|
--
|
|||||
Less:
Total Debt
|
$
|
172
|
$
|
172
|
|||
Aggregate
Equity Value of Minority Interests
|
$
|
10,928
|
$
|
15,428
|
|||
Primary
Shares Outstanding
|
5,200
|
5,200
|
|||||
Dilutive
Effect of Options
|
359
|
495
|
|||||
Diluted
Shares Outstanding
|
5,559
|
5,694
|
|||||
|
|||||||
Per
Share Value - Indication from Fundamental Valuation of
SBE
|
$
|
1.97
|
$
|
2.71
|
|||
(1)
Cash of $1.56 million as of January 31, 2005, is expected to be used
to
fund operating losses and therefore was not included in the equity
value
of SBE.
|
(in
thousands)
|
||||||||||
Low
|
High
|
|||||||||
Concluded
Equity Value of PyX
|
$
|
7,000
|
$
|
12,000
|
||||||
Consideration
Paid for PyX - Based on SBE Public Share Price
(1)
|
$
|
10,500
|
||||||||
Consideration
Paid for PyX - Based on SBE Public Share Price
(2)
|
|
$
|
11,100
|
|||||||
Consideration
Paid for PyX - Based on Fundamental SBE Valuation
|
$
|
6,500
|
--
|
$
|
9,000
|
(1)
Using the 20-Day Average Stock Price of $3.03 as of March 9,
2005.
|
||||||||||
(2)
Using the 20-Day Average Stock Price of $3.20 as of March 24,
2005.
|
•
|
the
tax or legal consequences of the merger;
|
•
|
the
net realizable value of our common stock or the prices at which our
common
stock may trade;
|
•
|
the
private placement; and
|
•
|
the
fairness of any aspect of the merger not expressly addressed in its
fairness opinion.
|
•
|
the
issued and outstanding shares of PyX common stock will be converted
into
the right to receive an aggregate of 2,561,050 shares of our common
stock,
or approximately 49% of the outstanding shares of our common stock
based
on the number of shares outstanding on June 9, 2005 and 24.6% of
the
outstanding shares of our common stock after the closing of the private
placement, assuming no further issuances of shares of our common
stock and
not exercise of outstanding stock options or warrants;
and
|
•
|
the
issued and outstanding options to purchase shares of PyX common stock
will
be assumed by us and converted into the right to receive an aggregate
of
2,038,950 shares of our common stock upon exercise of the underlying
options, or approximately 38.8% of the outstanding shares of our
common
stock based on the number of shares outstanding on June 9, 2005 and
19.6%
of the outstanding shares of our common stock after the closing of
the
private placement, assuming no further issuances of shares of our
common
stock and no exercise of outstanding stock options or warrants. The
options will be subject to the same terms and conditions as were
in place
prior to the merger.
|
•
|
the
organization, qualification and good standing of each of us, Merger
Sub
and PyX;
|
•
|
capitalization;
|
•
|
the
accuracy of each of our and PyX’s financial
statements;
|
•
|
PyX
and our authority to enter into, and carry out the obligations under,
the
merger agreement and the enforceability of the merger
agreement;
|
•
|
the
vote required to approve the merger by our stockholders and PyX’s
shareholders;
|
•
|
the
absence of conflicts, violations or defaults under each party’s
organizational documents, applicable laws and material
agreements;
|
•
|
the
absence of litigation matters involving the assets of the parties
or that
may have the effect of interfering with the merger;
and
|
•
|
finders’
or advisors’ fees.
|
•
|
the
accuracy of PyX’s books and
records;
|
•
|
the
absence of certain changes since February 28,
2005;
|
•
|
title
to, and absence of liens and encumbrances on, PyX’s
assets;
|
•
|
the
accuracy of information regarding accounts with financial institutions
and
the collectibility of PyX’s accounts
receivable;
|
•
|
the
condition and adequacy of PyX’s
assets;
|
•
|
PyX’s
intellectual property;
|
•
|
PyX’s
material contracts;
|
•
|
the
absence of undisclosed material liabilities of
PyX;
|
•
|
compliance
by PyX with applicable legal
requirements;
|
•
|
governmental
authorizations required in connection with the operation of PyX’s
business;
|
•
|
tax
matters;
|
•
|
employee
benefit and labor matters;
|
•
|
environmental
matters;
|
•
|
insurance;
and
|
•
|
the
absence of certain agreements, conflicts and/or other relationships
with
PyX’s officers, directors and other related
parties.
|
•
|
provide
us with reasonable access to PyX’s representatives, personnel, assets and
to all existing books, records, tax returns, work papers and other
documents and information relating to
PyX;
|
•
|
provide
us with copies of any existing books, records, tax returns, work
papers
and other documents and information relating to PyX;
and
|
•
|
provide
us with such additional financial, operating, and other data and
information regarding PyX as we may reasonably
request.
|
•
|
conduct
its business and operations in the ordinary course and in substantially
the same manner as conducted prior to the date of the merger
agreement;
|
•
|
use
reasonable efforts to preserve intact its current business organization,
keep available the services of its current officers and employees
and
maintain its relations and goodwill with persons having business
relationships with PyX;
|
•
|
keep
in full force all identified insurance
policies;
|
•
|
report
to us on at least a weekly basis concerning the status of PyX’s
business;
|
•
|
not
take certain actions with respect to PyX’s capital stock and option plans
and agreements relating to PyX’s capital
stock;
|
•
|
not
take any action with respect to PyX’s articles of incorporation or bylaws
or become a party to an alternative business combination
proposal;
|
•
|
not
form any subsidiary or acquire any interest in any other
entity;
|
•
|
not
make capital expenditures in excess of $5,000 per
month;
|
•
|
not
enter into or permit PyX’s assets to become bound by, any material
contract or amend, prematurely terminate or waive any material right
or
remedy under any material contract;
|
•
|
not
acquire, lease or license any right or other
asset;
|
•
|
not
sell, lease or license any right or other
asset;
|
•
|
waive
or relinquish any right other than assets acquired, leased, licensed
or
disposed of pursuant to immaterial
contracts;
|
•
|
not
lend money or incur or guarantee any indebtedness for borrowed
money;
|
•
|
not
establish, adopt or amend any employee benefit
plan;
|
•
|
not
pay any bonus or make any profit-sharing payment, cash incentive
payment
or similar payment to, or increase the amount of any compensation
payable
to any of its directors, officers or
employees;
|
•
|
not
hire any new employee;
|
•
|
not
change any of its methods of accounting or accounting practices in
any
material respect;
|
•
|
not
make any tax election;
|
•
|
not
commence or settle any material legal
proceeding;
|
•
|
not
make any payment to any third party without our consent in the event
we
make an extension of funds to PyX as provided below under “Exclusion
of Funds,”
on page __; and
|
•
|
not
agree or commit to take any of the above
actions.
|
•
|
solicit
or encourage the initiation of any inquiry, proposal or offer relating
to
an alternative business combination proposal;
|
•
|
participate
in any discussions or negotiations or enter into any agreement with,
or
furnish any non-public information to, any person relating to or
in
connection with any alternative business combination proposal;
or
|
•
|
consider,
entertain or accept any proposal or offer from any person relating
to any
alternative business combination
proposal.
|
•
|
the
discovery of any event, condition, fact or circumstance that occurred
or
existed on or prior to the date of the merger agreement that could
cause
or constitute an inaccuracy in or breach of any representation or
warranty
made by such party in the merger
agreement;
|
•
|
any
material breach of any covenant or obligation;
and
|
•
|
any
event, condition, fact or circumstance that would make the timely
satisfaction of any of the conditions set forth in the merger agreement
impossible or unlikely.
|
•
|
accuracy
of the other party’s representations and warranties and compliance by the
other party with their covenants;
|
•
|
approval
by our stockholders of the issuance of shares of our common stock
in
connection with the merger;
|
•
|
execution
and delivery of certain ancillary documents attached to the merger
agreement as exhibits;
|
•
|
receipt
of an officer’s certificate certifying the accuracy of each party’s
representations and warranties and satisfaction of certain conditions;
|
•
|
our
entering into a definitive agreement with respect to the private
placement;
|
•
|
absence
of legal prohibitions to the completion of the
merger;
|
•
|
absence
of legal proceedings challenging the merger, seeking recovery of
a
material amount in damages or seeking to prohibit or limit the exercise
of
any material right with respect to our ownership of stock in Merger
Sub or
the PyX shareholders’ ownership of our common stock;
and
|
•
|
no
material adverse effect will have occurred and no circumstance exists
that
could reasonably be expected to have or result in a material adverse
effect with respect to us or PyX.
|
•
|
holders
of no more than 5% of the outstanding PyX common stock will have
elected
to exercise their dissenters’ rights in connection with the
merger;
|
•
|
receipt
of required consents; and
|
•
|
amendment
of PyX’s current customer agreement with Pelco in a manner acceptable to
us.
|
•
|
if
it is reasonably determined by that party that timely satisfaction
of any
of the conditions precedent to the obligations of that party to effect
the
merger and consummate the transactions contemplated by the merger
agreement has become impossible;
|
•
|
if
any of the conditions precedent to the obligations of that party
to effect
the merger and consummate the transactions contemplated by the merger
agreement has not been satisfied as of the agreed closing date;
or
|
•
|
the
merger has not been completed on or before July 31,
2005.
|
•
|
our
investigation and review conducted with respect to PyX’s
business;
|
•
|
the
negotiation, preparation and review of the merger agreement and ancillary
agreements delivered or to be delivered in connection with the
transactions contemplated by the merger
agreement;
|
•
|
the
preparation and submission of any filing or notice required to be
made or
given in connection with, and the obtaining of any consent required
by,
any of the transactions contemplated by the merger
agreement;
|
•
|
our
preparation and audit of the PyX’s financial statements;
and
|
•
|
the
consummation of the merger.
|
|
|
Six-Month
Period Ended
|
|
Year
Ended
|
|||||
|
|
April
30, 2005 (SBE) of
March
31, 2005 (PyX)
|
|
October 31,
2004 (SBE) or
December
31, 2004 (PyX)
|
|||||
|
|
(Unaudited)
|
|||||||
SBE
Historical Per Share Data:
|
|
|
|||||||
|
Basic
and diluted net loss per common share
|
|
$(0.15)
|
|
$(0.33)
|
||||
|
Book
value per common share
|
|
$0.75
|
|
$0.83
|
||||
PyX
Historical Per Share Data:
|
|
|
|||||||
|
Basic
and diluted net loss per share
|
|
$(0.03)
|
|
$(0.05)
|
||||
|
Book
value (deficiency) per common share
|
|
$(0.00)
|
|
$(0.04)
|
||||
SBE
Pro Forma Combined:
|
|
|
|||||||
|
Basic
and diluted net loss per common share
|
|
$(0.25)
|
|
$(0.53)
|
||||
|
Book
value per share
|
|
$1.11
|
|
$1.11
|
||||
PyX
Equivalent Pro Forma Combined:
|
|
|
|||||||
|
Basic
and diluted net loss per common share
|
|
$(0.07)
|
|
$(0.11)
|
||||
|
Book
value per share
|
|
$(0.00)
|
|
$0.00
|
|
|
High
|
|
Low
|
|
|
|
|
|||
Fiscal
2004
|
|
|
|||
First
Quarter
|
|
$8.50
|
$5.52
|
||
|
(ended
January 31, 2004)
|
|
|||
Second
Quarter
|
|
7.38
|
3.63
|
||
|
(ended
April 30, 2004)
|
|
|||
Third
Quarter
|
|
4.40
|
2.81
|
||
|
(ended
July 31, 2004)
|
|
|||
Fourth
Quarter
|
|
4.10
|
2.54
|
||
|
(ended
October 31, 2004)
|
|
|||
Fiscal
2005
|
|
5.09
|
2.89
|
||
First
Quarter
|
|
||||
|
(ended
January 31, 2005)
|
|
3.79
|
2.57
|
|
Second
Quarter
|
|
|
|||
|
(ended
April 30, 2005)
|
|
3.55
|
2.30
|
SBE,
Inc.
Unaudited
Pro Forma Consolidated Balance Sheet)
|
|||||||||||||
April
30, 2005
|
March
31, 2005
|
||||||||||||
Historical
|
Historical
|
Combined
|
|||||||||||
SBE
|
PyX
|
Adjustments
|
As
Adjusted
|
||||||||||
(in
thousands
|
|||||||||||||
ASSETS
|
|||||||||||||
Current
assets:
|
|||||||||||||
Cash
and cash equivalents
|
$
|
1,221
|
$
|
79
|
$
|
4,800
|
a |
$
|
6,100
|
||||
Trade
accounts receivable, net
|
1,599
|
15
|
1,614
|
||||||||||
Inventories
|
1,474
|
-
|
1,474
|
||||||||||
Other
|
262
|
-
|
262
|
||||||||||
Total
current assets
|
4,556
|
94
|
4,800
|
9,450
|
|||||||||
Property
and equipment, net
|
392
|
20
|
412
|
||||||||||
Capitalized
software, net
|
149
|
-
|
149
|
||||||||||
Intellectual
property, net
|
-
|
-
|
9,987
|
b |
9,987
|
||||||||
Other
|
288
|
85
|
373
|
||||||||||
Total
assets
|
$
|
5,385
|
$
|
199
|
$
|
14,787
|
$
|
20,371
|
|||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|||||||||||||
Current
Liabilities:
|
|||||||||||||
Loan
|
$
|
-
|
$
|
10
|
$
|
10
|
|||||||
Trade
accounts payable
|
854
|
69
|
923
|
||||||||||
Accrued
payroll and employee benefits
|
329
|
26
|
355
|
||||||||||
Other
accrued expenses
|
164
|
-
|
164
|
||||||||||
Deferred
revenue
|
-
|
103
|
103
|
||||||||||
Capital
lease obligations
|
27
|
-
|
27
|
||||||||||
Total
liabilities
|
1,374
|
208
|
1,582
|
||||||||||
Long
term liabilities
|
135
|
-
|
135
|
||||||||||
Total
Liabilities
|
1,509
|
208
|
1,717
|
||||||||||
Stockholders'
equity
|
|||||||||||||
Common
Stock and additional paid in capital
|
16,175
|
365
|
11,862
|
b |
29,253
|
||||||||
|
4,800
|
a | |||||||||||
|
|||||||||||||
Deferred
compensation
|
(88
|
)
|
-
|
(1,876
|
) b |
(1,964
|
)
|
||||||
Retained
deficit
|
(12,211
|
)
|
(374
|
)
|
(12,585
|
)
|
|||||||
Total
stockholders' equity
|
3,876
|
(9
|
)
|
14,787
|
18,585
|
||||||||
Total
liabilities and stockholders' equity
|
$
|
5,385
|
$
|
199
|
$
|
14,787
|
$
|
20,371
|
(a)
|
Net
cash received from selling 2,575,000 shares of the Company’s common stock,
assuming a price per share of $2.00, and warrants to purchase 1,287,500
shares of SBE common stock, assuming an exercise price per share
of $2.66,
in the private placement, net of $350,000 of estimated offering
expenses
and of expenses related to the PyX acquisition. The assumed price
per
share is based on the lowest unit price at which the Company is
obligated
to complete the private placement.
|
b)
|
In
the PyX acquisition, the Company will issue 2,561,050 shares of
the
Company’s common stock with an assumed value of $3.09 per share for
payment to the selling shareholders of PyX for the acquisition
of PyX. The
assumed price per share is based on the average closing price for
the
Company’s common stock over the period beginning five trading days prior
to and ending five trading days after the date the merger agreement
was
signed, March 28, 2005. In addition, the Company will assume the
PyX stock
option plan with the outstanding PyX stock options converted into
options
to purchase 2,038,950 shares of the Company’s common stock. These
replacement options vest over 4 years and the PyX employees must
continue
to an employee of the Company during the vesting period. The fair
value of
each option grant is estimated on the date of grant using the
Black-Scholes option-pricing model with the following weighted-average
assumptions used for grants in 2005: Dividend yield of 0%; expected
volatility of 70.0%, risk-free interest rate of 3.0%, and expected
life of
four years. The assumed price per share is based on the average
closing
price for the Company’s common stock over the period beginning five
trading days prior to and ending five trading days after the date
the
merger agreement was signed, March 28, 2005.
|
|
|
The
purchase price of $11,862,000 related to the shares of the Company’s
common stock issued to selling shareholders of PyX and the issuance
of
options to purchase the Company’s common stock is allocated to as follows:
$9,987,000 to Intellectual Property, which is the estimated fair
value of
the PyX intellectual property, associated with current and future
products
acquired in the acquisition of PyX and $1,876,000 to deferred
compensation. The deferred compensation is calculated as the difference
between the stock option strike price of $2.17 per share and the
assumed
value of $3.09 per share. The assumed price per share is based
on the
average closing price for the Company’s common stock over the period
beginning five trading days prior to and ending five trading days
after
the date the merger agreement was signed, March 28, 2005. The Company
amortizes deferred compensation to expense on a straight-line basis
over
the vesting period of the underlying options to purchase the Company’s
common stock, in this case 4 years. Deferred compensation expense
totaling
$281,000 per year will be included in the Company’s product research and
development expense and deferred compensation expense totaling
$188,000
per year will be included in the Company’s sales and marketing expense for
a total of $469,000 of annual deferred compensation amortization
expense.
|
SBE,
Inc.
Unaudited Pro Forma Condensed Combined Statement of Operations |
|||||||||||||
for
the six months ended
|
|||||||||||||
April
30, 2005
|
March
31, 2005
|
||||||||||||
Historical
|
Historical
|
Combined
|
|||||||||||
SBE
|
PyX
|
Adjustments
|
Companies
|
||||||||||
(in
thousands, except for per share amounts)
|
|||||||||||||
Net
Sales
|
$
|
4,520
|
$
|
-
|
$
|
$
|
$4,520
|
||||||
Cost
of Sales
|
2,305
|
-
|
1,664
|
a |
3,969
|
||||||||
Gross
Profit
|
2,215
|
-
|
(1,664
|
)
|
551
|
||||||||
|
|||||||||||||
Product
research and development
|
1,048
|
91
|
367
|
b |
1,506
|
||||||||
Sales
and marketing
|
1,053
|
48
|
263
|
c |
1,364
|
||||||||
General
and administrative
|
795
|
34
|
-
|
829
|
|||||||||
Total
operating expense
|
2,967
|
173
|
630
|
3,699
|
|||||||||
|
|||||||||||||
Operating
income loss
|
(752
|
)
|
(173
|
)
|
(2,294
|
)
|
(3,148
|
)
|
|||||
|
|||||||||||||
Interest
income (expense)
|
(3
|
)
|
-
|
-
|
(3
|
)
|
|||||||
|
|||||||||||||
Net
loss before income taxes
|
(755
|
)
|
(173
|
)
|
(2,294
|
)
|
(3,151
|
)
|
|||||
Provision
for income taxes
|
5
|
-
|
-
|
5
|
|||||||||
|
|||||||||||||
Net
loss
|
$
|
(760
|
)
|
$
|
(173
|
)
|
$
|
(2,294
|
)
|
$
|
(3,156
|
)
|
|
|
|||||||||||||
Basic
loss per share
|
$
|
(0.15
|
)
|
$
|
$
|
|
$
|
(0.31
|
)
|
||||
Diluted
loss per share
|
$
|
(0.15
|
)
|
$
|
$
|
|
$
|
(0.31
|
)
|
||||
|
|||||||||||||
Basic
- shares used in per share
computations |
5,175
|
5,136
|
d |
10,311
|
|||||||||
Diluted
- shares used in per share
computations |
5,175
|
5,136
|
d |
10,311
|
(a)
|
The
intellectual property acquired in the PyX acquisition is amortized
to
expense over 36 months. This $1,664,000 adjustment reflects six
months of
amortization of intellectual property originally valued at $9,987,000
acquired in the PyX acquisition.
|
(b)
|
Adjustment
to reflect the difference between the current salaries plus benefits
of
the PyX engineering employees and the expected salaries plus
benefits of
the PyX engineering employees when they are hired by the Company.
Included
in this adjustment is $141,000 of amortization expense related
to
six-months of amortization of deferred compensation related to
the
issuance of options to purchase the Company’s common stock awarded to the
engineering employees of PyX as part of the purchase price of
PyX. The
deferred compensation related to the purchase price of PyX totals
$1,876,000 and will be amortized to product research and development
and
sales and marketing expense over the 4-year vesting period of
the options.
This adjustment is for the six-month period from November 1,
2004 through
April 30, 2005.
|
(c)
|
Adjustment
to reflect the difference between the current salaries plus benefits
of
the PyX sales employees and the expected salaries plus benefits
of the PyX
sales employees when they are hired by the Company. Included
in this
adjustment is $94,000 of amortization expense related to six-months
of
amortization of deferred compensation related to the issuance
of options
to purchase the Company’s common stock awarded to the sales and marketing
employees of PyX as part of the purchase price of PyX. The deferred
compensation related to the purchase price of PyX totals $1,876,000
and
will be amortized to product research and development and sales
and
marketing expense over the 4-year vesting period of the options.
This
adjustment is for the six-month period from November 1, 2004
through April
30, 2005.
|
(d)
|
Combined
pro forma shares include 2,561,050 shares of the Company’s common stock
that the Company will be issuing to the shareholders of PyX,
at an assumed
price of $3.09 per share based on the average closing price for
the
Company’s common stock over the period beginning five trading days prior
to and ending five trading days after the date the merger agreement
was
signed, March 28, 2005, plus 2,575,000 shares of the Company’s common
stock in the private placement equity transaction at an assumed
price of
$2.00 per share, which is based on the lowest unit price at which
the
Company is obligated to complete the private placement. The following
securities were not included in the computation of pro forma
number of
shares because to do so would have been antidilutive for the
periods
presented:
|
SBE
outstanding employee stock options
|
2,307,627
|
|||
Warrants
to purchase SBE common stock
|
140,000
|
|||
PyX
outstanding employee stock options to be assumed by SBE
|
2,038,950
|
|||
Warrants
to purchase SBE common stock issued in conjunction with the private
placement transaction
|
1,287,500
|
|||
Total
securities not included in pro forma number of shares
|
5,774,077
|
for
the year ended
|
|||||||||||||
October
31, 2004
Historical
SBE
|
December
31, 2004
Historical
PyX
|
Adjustments
|
Combined
Companies
|
||||||||||
(in
thousands, except for per share
amounts)
|
|||||||||||||
Net
Sales
|
$
|
11,066
|
$
|
-
|
$ |
$
|
11,066
|
||||||
Cost
of Sales
|
6,646
|
-
|
3,329
|
a |
9,975
|
||||||||
Gross
Profit
|
4,420
|
-
|
3,329
|
1,092
|
|||||||||
Product
research and development
|
2,411
|
143
|
735
|
b |
3,289
|
||||||||
Sales
and marketing
|
2,177
|
125
|
525
|
c |
2,827
|
||||||||
General
and administrative
|
1,755
|
-
|
1,755
|
||||||||||
Loan
reserve
|
(239
|
)
|
-
|
(239
|
)
|
||||||||
Total
operating expense
|
6,104
|
268
|
1,260
|
7,632
|
|||||||||
Operating
loss
|
(1,684
|
)
|
(268
|
)
|
(4,589
|
)
|
(6,541
|
)
|
|||||
Interest
income (expense)
|
5
|
-
|
5
|
||||||||||
Net
loss before income taxes
|
(1,679
|
)
|
(268
|
)
|
(4,589
|
)
|
(6,536
|
)
|
|||||
Benefit
for income taxes
|
-
|
-
|
|||||||||||
Net
loss
|
$
|
(1,679
|
)
|
$
|
(268
|
)
|
$
|
(4,589
|
)
|
$
|
(6,536
|
)
|
|
Basic
loss per share
|
$
|
(0.33
|
)
|
$ |
$
|
|
$
|
(0.64
|
)
|
||||
Diluted
loss per share
|
$
|
(0.33
|
)
|
$ |
$
|
|
$
|
(0.64
|
)
|
||||
Basic
- shares used in per share
computations |
5,022
|
5,136
|
d |
10,158
|
|||||||||
Diluted
- shares used in per share
computations |
5,022
|
5,136
|
d |
10,158
|
(a)
|
The
intellectual property acquired in the PyX acquisition is amortized
to
expense over 36 months. This $3,329,000 adjustment reflects twelve
months
amortization of intellectual property originally valued at $9,987,000
acquired in the PyX acquisition.
|
(b)
|
Adjustment
to reflect the difference between the current salaries plus benefits
of
the PyX engineering employees and the expected salaries plus
benefits of
the PyX engineering employees when they are hired by the Company.
Included
in this adjustment is $281,000 of amortization expense related
to
twelve-months of amortization of deferred compensation related
to the
issuance of options to purchase the Company’s common stock awarded to the
engineering employees of PyX as part of the purchase price of
PyX. The
deferred compensation related to the purchase price of PyX totals
$1,876,000 and will be amortized to product research and development
and
sales and marketing expense over the 4-year vesting period of
the options.
This adjustment is for the twelve-month period from November
1, 2003
through October 31, 2004.
|
(c) | Adjustment to reflect the difference between the current salaries plus benefits of the PyX sales employees and the expected salaries plus benefits of the PyX sales employees when they are hired by the Company. Included in this adjustment is $188,000 of amortization expense related to twelve-months of amortization of deferred compensation related to the issuance of options to purchase the Company’s common stock awarded to the sales and marketing employees of PyX as part of the purchase price of PyX. The deferred compensation related to the purchase price of PyX totals $1,876,000 and will be amortized to product research and development and sales and marketing expense over the 4-year vesting period of the options. This adjustment is for the twelve-month period from November 1, 2003 through October 31, 2004. |
(d) |
Combined
pro forma shares include 2,561,050 shares of the Company’s common stock
that the Company will be issuing to the shareholders of PyX,
at an assumed
price of $3.09 per share is based on the average closing price
for the
Company’s common stock over the period beginning five trading days prior
to and ending five trading days after the date the merger agreement
was
signed, March 28, 2005, plus 2,575,000 shares of the Company’s common
stock that the Company will be selling to the purchasers in the
private
placement equity transaction at an assumed price of $2.00 per
share, which
is based on the lowest unit price at which the Company is obligated
to
complete the private placement. The following securities were
not included
in the computation of pro forma number of shares because to do
so would
have been antidilutive for the periods
presented:
|
SBE
outstanding employee stock options
|
2,307,627
|
|||
Warrants
to purchase SBE common stock
|
140,000
|
|||
PyX
outstanding employee stock options to be assumed by SBE
|
2,038,950
|
|||
Warrants
to purchase SBE common stock issued in conjunction with the private
placement transaction
|
1,287,500
|
|||
Total
securities not included in pro forma number of shares
|
5,774,077
|
January
1, 2005
to March 31, 2005 |
January
1, 2004
to March 31, 2004 |
January
1, 2004
to December
31,2004
|
Period
from Inception
to December 31, 2003 |
||||||||||
Statements
of Operations Data:
|
|||||||||||||
Total
revenues
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
5,000
|
|||||
Total
operating expenses
|
466,255
|
6,579
|
267,432
|
26,696
|
|||||||||
Operating
loss
|
(466,255
|
)
|
(6,579
|
)
|
(267,432
|
)
|
(21,696
|
)
|
|||||
Net
loss
|
(467,255
|
)
|
(6,579
|
)
|
(268,463
|
)
|
(22,510
|
)
|
March
31,
2005 |
2004
|
December
31, 2003 |
|||||||||||
Balance
Sheet Data:
|
|||||||||||||
Total
current assets
|
$
|
93,897
|
$
|
$
|
$4,869
|
$
|
392
|
||||||
Total
assets
|
198,864
|
41,449
|
11,982
|
||||||||||
Total
current liabilities
|
207,187
|
219,922
|
1,992
|
||||||||||
Total
liabilities
|
207,187
|
219,922
|
1,992
|
||||||||||
Total
shareholders' equity (deficit)
|
$
|
(8,323
|
)
|
$
|
|
$
|
$(178,473
|
)
|
$
|
9,990
|
Quarter
Ended
|
Quarter
Ended
|
January
1, 2004 to
|
Period
from Inception
|
||||||||||
March
31, 2005
|
March
31, 2005
|
December
31, 2004
|
to
December 31, 2003
|
||||||||||
Total
revenue
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
5,000
|
|||||
Total
operating expenses
|
466,255
|
6,579
|
267,442
|
26,696
|
|||||||||
Operating
loss
|
(466,255
|
)
|
(6,579
|
)
|
(267,442
|
)
|
(21,696
|
)
|
|||||
Interest
expense
|
200
|
|
200
|
- | |||||||||
Income
(loss) before income taxes
|
(466,455
|
)
|
(6,579
|
)
|
(267,642
|
)
|
(21,696
|
)
|
|||||
Income
tax expense
|
800
|
-
|
831
|
814
|
|||||||||
Net
loss
|
$
|
(467,255
|
)
|
$
|
(6,579
|
)
|
$
|
(268,473
|
)
|
$
|
(22,510
|
)
|
Page
|
|
Report
of Independent Registered Public Accounting Firm
|
3
|
Balance
Sheets
|
4
|
Statements
of Operations
|
5
|
Statements
of Shareholders’ Equity
|
6
|
Statements
of Cash Flows
|
7
|
Summary
of Accounting Policies
|
8
|
Notes
to Financial Statements
|
8
|
(unaudited)
March 31, |
December
31,
|
|||||||||
2005
|
2004
|
2003
|
||||||||
Assets
|
||||||||||
Current
Assets
|
||||||||||
Cash
|
$
|
78,847
|
$
|
4,869
|
$
|
392
|
||||
Accounts
receivable
|
15,050
|
-
|
-
|
|||||||
Total
current assets
|
93,897
|
4,869
|
392
|
|||||||
Property
and equipment, net
|
20,467
|
12,580
|
11,982
|
|||||||
Other
assets
|
84,500
|
24,000
|
-
|
|||||||
Total
Assets
|
$
|
198,864
|
$
|
41,449
|
$
|
11,982
|
||||
Liabilities
and Shareholders’ Equity
|
||||||||||
Current
Liabilities
|
||||||||||
Loans
|
$
|
10,400
|
$
|
10,200
|
$
|
-
|
||||
Accounts
payable
|
68,608
|
82,870
|
1,992
|
|||||||
Accrued
payroll and employee benefits
|
26,179
|
44,352
|
-
|
|||||||
Deferred
revenues
|
102,000
|
82,500
|
-
|
|||||||
Total
current liabilities
|
207,187
|
219,922
|
1,992
|
|||||||
Total
liabilities
|
207,187
|
219,922
|
1,992
|
|||||||
Commitments
and contingencies
|
||||||||||
Stockholders’
equity (deficit)
|
||||||||||
Common
stock
|
||||||||||
($0.001
par value); authorized 10,000,000, 10,000,000 and 200,000 shares;
issued
and outstanding 5,567,500, 5,102,500 and 100,450
|
1,549
|
1,084
|
1,004
|
|||||||
Additional
paid-in capital
|
4,607,271
|
111,416
|
31,496
|
|||||||
Deferred
compensation
|
(3,858,915
|
)
|
---
|
---
|
||||||
Deficit
accumulated during the development stage
|
(758,228
|
)
|
(290,973
|
)
|
(22,510
|
)
|
||||
Total
shareholders’ equity (deficit)
|
(8,323
|
)
|
(178,473
|
)
|
9,990
|
|||||
Total
liabilities and shareholders’ equity (deficit)
|
$
|
198,864
|
$
|
41,449
|
$
|
11,982
|
(unaudited)
January
1,
2005 to March 31, 2005 |
(unaudited)
January 1, 2004 to March 31, 2004 |
January
1,
2004 to December 31, 2004 |
Period
from
Inception to December 31, 2003 |
Cumulative
from Inception to March, 31 2005 |
||||||||||||
Service
contract revenues
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
5,000
|
$
|
5,000
|
||||||
Total
revenues
|
-
|
-
|
-
|
5,000
|
5,000
|
|||||||||||
Costs
and expenses
|
||||||||||||||||
Product
research and development
|
46,732
|
3,379
|
142,625
|
13,808
|
203,165
|
|||||||||||
Selling,
general and administrative
|
419,523
|
3,200
|
124,807
|
12,888
|
557,218
|
|||||||||||
Total
operating expenses
|
466,255
|
6,579
|
267,432
|
26,696
|
760,383
|
|||||||||||
Operating
loss
|
(466,255
|
)
|
(6,579
|
)
|
(267,432
|
)
|
(21,696
|
)
|
(755,383
|
)
|
||||||
Interest
expense
|
200
|
-
|
200
|
-
|
400
|
|||||||||||
Loss
before income taxes
|
(466,455
|
)
|
(6,579
|
)
|
(267,632
|
)
|
(21,696
|
)
|
(755,783
|
)
|
||||||
Income
tax expense
|
800
|
-
|
831
|
814
|
2,445
|
|||||||||||
Net
loss
|
$
|
(467,255
|
)
|
$
|
(6,579
|
)
|
$
|
(268,463
|
)
|
$
|
(22,510
|
)
|
$
|
(758,228
|
)
|
Common
Stock and Additional
Paid-in
Capital
|
|||||||||||||||||||
Shares
|
Par
Value
|
Additional
Paid-in Capital
|
Deferred
Compensation
|
Accumulated
Deficit
|
Total
|
||||||||||||||
Balance,
November 26, 2002
|
$
|
---
|
$
|
---
|
$
|
---
|
$
|
---
|
$
|
---
|
$
|
---
|
|||||||
Stock
issued to founders
|
5,000,000
|
1,000
|
9,000
|
---
|
---
|
10,000
|
|||||||||||||
Stock
issued in connection with private placement
|
22,500
|
4
|
22,496
|
---
|
---
|
22,500
|
|||||||||||||
Net
loss
|
---
|
---
|
---
|
---
|
(22,510
|
)
|
(22,510
|
)
|
|||||||||||
Balance,
December 31, 2003
|
5,022,500
|
1,004
|
31,496
|
---
|
(22,510
|
)
|
9,990
|
||||||||||||
Stock
issued in connection with private placement
|
80,000
|
80
|
79,920
|
---
|
---
|
80,000
|
|||||||||||||
Net
loss
|
--
|
---
|
--
|
---
|
(268,463
|
)
|
(268,463
|
)
|
|||||||||||
Balance,
December 31, 2004
|
5,102,500
|
1,084
|
111,416
|
---
|
(290,973
|
)
|
(178,473
|
)
|
|||||||||||
Stock
issued in connection with private placement
|
250,000
|
250
|
249,750
|
---
|
---
|
250,000
|
|||||||||||||
Warrants
to purchase stock issued in connection with employment
|
215,000
|
215
|
305,085
|
---
|
---
|
305,300
|
|||||||||||||
Deferred
compensation included in common stock
|
3,941,020
|
---
|
3,941,020
|
||||||||||||||||
Deferred
compensation
|
(3,858,915
|
)
|
(3,858,915
|
)
|
|||||||||||||||
Net
loss
|
--
|
---
|
--
|
---
|
(467,255
|
)
|
(467,255
|
)
|
|||||||||||
Balance,
March 31, 2005 (unaudited)
|
5,567,500
|
$
|
1,549
|
$
|
4,607,271
|
$
|
(3,858,915
|
)
|
$
|
(758,228
|
)
|
$
|
(8,323
|
)
|
PYX
TECHNOLOGIES, INC.
|
||||||||
(A
DEVELOPMENT STAGE COMPANY)
|
||||||||
STATEMENTS
OF CASH FLOWS
|
(unaudited)
Quarter Ended March 31, 2005 |
(unaudited)
Quarter Ended March 31, 2004 |
Year
Ended
December 31, 2004 |
Period
from
Inception (November 26, 2002) through December 31, 2003 |
Period
from
Inception (November 26, 2002) through March 31, 2005 |
||||||||||||
Cash
flows from operating activities:
|
||||||||||||||||
Net
loss
|
(467,255
|
)
|
(6,579
|
)
|
(268,463
|
)
|
(22,510
|
)
|
(758,228
|
)
|
||||||
Adjustments
to reconcile net loss to net cash used
in operating activities:
|
||||||||||||||||
Depreciation
|
2,125
|
1,116
|
5,447
|
1,812
|
9,384
|
|||||||||||
Stock
based compensation expense
|
385,255
|
-
|
-
|
385,255
|
||||||||||||
Changes
in operating assets and liabilities:
|
||||||||||||||||
Account
receivable
|
(15,050
|
)
|
-
|
-
|
-
|
(15,050
|
)
|
|||||||||
Other
assets
|
(60,500
|
)
|
-
|
(24,000
|
)
|
---
|
(84,500
|
)
|
||||||||
Accounts
payable
|
(14,062
|
)
|
-
|
80,879
|
1,992
|
68,608
|
||||||||||
Accrued
payroll and commissions
|
(18,173
|
)
|
-
|
44,351
|
---
|
26,179
|
||||||||||
Deferred
revenues
|
19,500
|
5,000
|
82,500
|
---
|
102,000
|
|||||||||||
Net
cash used in operating activities
|
(168,160
|
)
|
(463
|
)
|
(79,286
|
)
|
(18,706
|
)
|
(266,352
|
)
|
||||||
Cash
flows from investing activities:
|
||||||||||||||||
Purchases
of property and equipment
|
(10,012
|
)
|
(734
|
)
|
(6,437
|
)
|
(13,402
|
)
|
(29,851
|
)
|
||||||
Net
cash used in investing activities
|
(10,012
|
)
|
(734
|
)
|
(6,437
|
)
|
(13,402
|
)
|
(29,851
|
)
|
||||||
Cash
flows from financing activities:
|
||||||||||||||||
Loan
|
-
|
-
|
10,200
|
---
|
10,400
|
|||||||||||
Proceeds
from issuance of common stock
|
252,150
|
30,000
|
80,000
|
32,500
|
364,650
|
|||||||||||
Net
cash provided by financing activities
|
252,150
|
30,000
|
90,200
|
32,500
|
375,050
|
|||||||||||
Net
increase in cash
and cash
equivalents
|
73,978
|
28,803
|
4,477
|
392
|
79,847
|
|||||||||||
Cash
at beginning of year
|
4,869
|
392
|
392
|
---
|
-
|
|||||||||||
Cash
at end of year
|
78,847
|
29,195
|
4,869
|
392
|
78,847
|
|||||||||||
Interest
paid
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
Income
tax paid
|
-
|
-
|
800
|
-
|
800
|
March
31,
|
December
31,
|
December
31,
|
||||||||
2005
|
2004
|
2003
|
||||||||
Computer
hardware
|
$
|
29,851
|
$
|
19,839
|
$
|
13,402
|
||||
Less
accumulated depreciation and amortization
|
(9,384
|
)
|
(7,259
|
)
|
(1,812
|
)
|
||||
$
|
20,467
|
$
|
12,580
|
$
|
11,590
|
Name
|
Investment
|
Herschel
Berkowitz
|
$150,000.00
|
Paul
Packer
|
50,000.00
|
Globis
Capital Partners
|
500,000.00
|
Globis
Overseas Fund Ltd.
|
200,000.00
|
Richard
Grossman
|
50,000.00
|
Joshua
Hirsch
|
50,000.00
|
James
Kardon
|
17,000.00
|
AIGH
Investment Partners LLC
|
825,000.00
|
Ellis
International LLC
|
100,000.00
|
Jack
Dodick
|
200,000.00
|
Stephen
Spira
|
100,000.00
|
Fame
Associates
|
100,000.00
|
Cam
Co
|
350,000.00
|
Anfel
Trading Limited
|
650,000.00
|
Ganot
Corporation
|
350,000.00
|
LaPlace
Group, LLC
|
300,000.00
|
F.
Lyon Polk
|
60,000.00
|
Paul
Tramontano
|
50,000.00
|
Hilary
Edson
|
60,000.00
|
Kevin
McCaffrey
|
100,000.00
|
William
Heinzerling
|
100,000.00
|
John
A. Moore
|
100,000.00
|
Mark
Giordano
|
30,000.00
|
Jeffrey
Schwartz
|
8,000.00
|
Norman
Pessin
|
250,000.00
|
Greg
Yamamoto
|
200,000.00
|
Tzu-Wang
Pan
|
50,000.00
|
Kurt
Miyatake
|
50,000.00
|
Greg
Yamamoto, as UTMA custodian for Melanie
Yamamoto
|
50,000.00
|
Greg
Yamamoto, as UTMA custodian for Nicholas
Yamamoto
|
50,000.00
|
Total
|
$5,150,000.00
|
•
|
$2.50; |
•
|
92%
of the average closing sale price per share of our common stock,
as
reported on the Nasdaq SmallCap Market, for each of the five consecutive
trading days on which our common stock trades ending on the date
immediately prior to the closing date of the private placement;
and
|
•
|
95%
of the closing sale price per share of our common stock, as reported
on
the Nasdaq SmallCap Market, on the trading day on which our common
stock
trades that immediately precedes the closing date of the private
placement.
|
•
|
the
purchasers and our authority to enter into, and carry out the obligations
under, the unit subscription agreements and the enforceability of
the unit
subscription agreements; and
|
•
|
retention
of brokers or finders in connection with the private
placement.
|
•
|
our
organization, qualification, corporate power and good
standing;
|
•
|
the
organization, qualification and good standing of each of our subsidiaries,
including, for purposes of the unit subscription agreements, of
PyX;
|
•
|
capitalization;
|
•
|
this
proxy statement and the special
meeting;
|
•
|
the
authorization of shares of common stock and the warrants to purchase
shares of common stock to be issued pursuant to the unit subscription
agreements;
|
•
|
the
exemption of the units from the registration requirements of the
Securities Act of 1933, as amended;
|
•
|
the
absence of certain conflicts;
|
•
|
receipt
of all necessary governmental authorizations required in connection
with
the private placement;
|
•
|
compliance
with applicable legal requirements and material
agreements;
|
•
|
the
accuracy of certain of our SEC filings and our financial
statements;
|
•
|
litigation
matters;
|
•
|
the
absence of certain changes since January 31,
2005;
|
•
|
our
intellectual property;
|
•
|
adverse
business developments;
|
•
|
outstanding
registration rights;
|
•
|
the
accuracy of our charter documents as provided to the purchasers;
and
|
•
|
our
use of the proceeds from the private
placement.
|
•
|
execution
and delivery of the investor rights
agreement;
|
•
|
accuracy
of the representations and warranties of the parties and compliance
by the
parties with their respective
covenants;
|
•
|
the
approval of Proposals 1 and 2;
|
•
|
our
listing status on the Nasdaq SmallCap
Market;
|
•
|
completion
of the merger; and
|
•
|
entry
by PyX into a reseller agreement with LSI
Logic.
|
|
|
|
By
Order of the Board of Directors,
|
|
|
|
|
|
/s/
David W. Brunton
|
|
|
|
David
W. Brunton
|
|
Secretary
|
Amount
of Subscription:
$_____________
|
___________________________________
Print
Name
|
___________________________________
Signature
of Investor
|
|
___________________________________
Social
Security Number
|
|
___________________________________
Address
and Fax Number
|
|
___________________________________
E-mail
Address
|
|
Amount
of Subscription:
$__________________
|
___________________________________
Print
Name of Purchaser
|
___________________________________
Signature
of a Purchaser
|
|
___________________________________
Social
Security Number
|
|
___________________________________
Print
Name of Spouse or Other Purchaser
|
|
___________________________________
Signature
of Spouse or Other Purchaser
|
|
___________________________________
Social
Security Number
|
|
___________________________________
Address
|
|
___________________________________
|
|
Fax
Number
|
|
____________________________________
E-mail
Address
|
Amount
of Subscription:
$____________
|
|
___________________________________
Print
Full Legal Name of Partnership,
Company,
Limited Liability Company, Trust or Other Entity
|
|
By:
__________________________________
(Authorized
Signatory)
|
|
Name:
________________________________
|
|
Title:
_________________________________
|
|
Address
and Fax Number: _____________
___________________________________
|
|
Taxpayer
Identification Number: __________
|
|
Date
and State of Organization:__________
|
|
Date
on which Taxable Year Ends:________
|
|
E-mail
Address: ________________________
|
Name
|
Total
Purchase Price
|
Herschel
Berkowitz
|
$150,000.00
|
Paul
Packer
|
50,000.00
|
Globis
Capital Partners
|
500,000.00
|
Globis
Overseas Fund Ltd.
|
200,000.00
|
Richard
Grossman
|
50,000.00
|
Joshua
Hirsch
|
50,000.00
|
James
Kardon
|
17,000.00
|
AIGH
Investment Partners LLC
|
825,000.00
|
Ellis
International LLC
|
100,000.00
|
Jack
Dodick
|
200,000.00
|
Stephen
Spira
|
100,000.00
|
Fame
Associates
|
100,000.00
|
Cam
Co
|
350,000.00
|
Anfel
Trading Limited
|
650,000.00
|
Ganot
Corporation
|
350,000.00
|
LaPlace
Group, LLC
|
300,000.00
|
F.
Lyon Polk
|
60,000.00
|
Paul
Tramontano
|
50,000.00
|
Hilary
Edson
|
60,000.00
|
Kevin
McCaffrey
|
100,000.00
|
William
Heinzerling
|
100,000.00
|
John
A. Moore
|
100,000.00
|
Mark
Giordano
|
30,000.00
|
Jeffrey
Schwartz
|
8,000.00
|
Norman
Pessin
|
250,000.00
|
Greg
Yamamoto
|
200,000.00
|
Tzu-Wang
Pan
|
50,000.00
|
Kurt
Miyatake
|
50,000.00
|
Greg
Yamamoto, as UTMA custodian for
Melanie Yamamoto |
50,000.00
|
Greg
Yamamoto, as UTMA custodian for
Nicholas Yamamoto |
50,000.00
|
TOTAL
|
$5,150,000.00
|
Schedule
1.1(b)
|
Investors
|
Exhibit
1:
|
Form
of Warrants
|
Exhibit
2:
|
Voting
Agreement
|
Exhibit
3:
|
Form
of Investor Rights Agreement
|
Exhibit
4:
|
Matters
Covered by Legal
Opinion
|
SBE, INC. | ||
|
|
|
By: | /s/ | |
Name: |
||
Title: |
INVESTORS: | ||
Name: |
||
|
[ |
] |
By: | /s/ | |
Name: |
||
Title: |